Biotex Pharma Investments, LLC Form SC 13G/A November 12, 2009

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this for securities, and for any subsequent amendment containing information which would alter the disclosures pro-	1 0
The information required in the remainder of this cover page shall not be deemed to be "filed" for the Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be (however, see the Notes).	
I	

1.	Names of Reportin	g Person	s.	
	I.R.S. Identificatio	n Nos. of	above persons (entities only).	
	Biotex Pharma Inv	estments	, LLC	
2.	Check the Appropr	riate Box	if a Member of a Group (See Instruction	ons)
	(a)			
	(b)			
3.	SEC Use Only			
4.	Citizenship or Plac	e of Orga	anization	
	Delaware			
		5.	Sole Voting Power 17,395,000	
Number Shares Benefici		6.	0	
Owned I Reportir Person V	ıg	7.	Sole Dispositive Power 17,395,000	
		8.	Shared Dispositive Power 0	
9.	Aggregate Amoun	t Benefic	ially Owned by Each Reporting Person	17,395,000
10.	Check box if the A	ggregate	Amount in Row (9) Excludes	
	Certain Shares (Se	e Instruct	tions)	N/A

11.	Percent of Class Represented by Amount in Row (9)
	9.38% (based on 185,501,158 shares of common stock outstanding as of October 5, 2009, as reported in the Issuer's Registration Statement on Form S-1, filed with the Securities and Exchange Commission on October 7, 2009).
12.	Type of Reporting Person (See Instructions) 00
2	

Item 1(a).	Name of Issuer:
Soligenix, Inc.	
Item 1(b).	Address of Issuer's Principal Executive Offices:
29 Emmons Drive,	Suite C-10, Princeton, NJ 08540
Item 2(a).	Name of Person Filing:
This statement is fi	led on behalf of each of the following persons (collectively, the "Reporting Persons")
	Biotex Pharma Investments, LLC
Item 2(b).	Address of Principal Business Office:
E	Biotex Pharma Investments, LLC
2	20 W. 42nd Street, 6th Floor
1	Jew York, NY 10036
Item 2(c).	Citizenship:
	Biotex Pharma Investments, LLC is a Delaware limited liability company.
Item 2(d).	Title of Class of Securities:
Common Stock, pa	r value \$0.001 (the "Shares")

Item 2(e).	CUSIP Number:
258094101	
Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a:
This Item 3 is not a	pplicable
3	

Item 4.	Ownersh	nip:	
	(a) Amo	unt beneficially owned:	17,395,000
	(b) Perce	ent of class:	9.38%
	(c) Num	ber of shares as to which such person has:	
	(i)	sole power to vote or to direct the vote:	17,395,000
	(ii)	shared power to vote or to direct the vote:	0
	(iii) (iv)	sole power to dispose or to direct the disposition of: shared power to dispose or to direct the disposition of:	17,395,000 0
Item 5.	Ownersh	nip of Five Percent or Less of a Class:	
Not Applicable			
Item 6.	Ownersh	nip of More than Five Percent on Behalf of Another Person:	
Not Applicable			
Item 7.		cation and Classification of the Subsidiary Which Acquired the Security Being Reported o Company:	n by the Parent
Not Applicable			

Item 8.	Identification and Classification of Members of the Group:
Not Applicable	
Item 9.	Notice of Dissolution of Group:
Not Applicable	
4	

Item 10	Certification:

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 9, 2009

BIOTEX PHARMA INVESTMENTS, LLC

By: /s/ Robert Kessler Name: Robert Kessler Title: Member